Home > Boards > Free Zone > Health and Sciences > Biotech Values

BPAX is trading for less than cash (cash

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
jaybird249 Member Profile
 
Followed By 80
Posts 2,931
Boards Moderated 0
Alias Born 05/05/06
160x600 placeholder
Kansas City Fed Services Activity Index Rises in January
By Colin Kellaher
Apple Up Over 5%, on Track for Largest Percent Increase Since October 2020 -- Data Talk
Intel on Track for Lowest Close Since December 2020 -- Data Talk
Visa Up Over 5%, on Pace for Largest Percent Increase Since November 2020 -- Data Talk
Oil Prices Seen at $78 This Year as Supply Hikes Lag Demand
US Consumer Sentiment Wanes in Late January to Decade-Low on Inflation Concerns
Insulet Shares Rally on FDA Approval of Omnipod 5
Provention Bio Shares Rise 13% After Plan to Resubmit BLA
Pfizer Gets EC OK for Lorviqua as First-Line Treatment for ALK-Positive Advanced Lung Cancer
Citi Works With Five Black-Owned Firms on Bond Issuance
Top Company News of the Day
U.S. Consumer Spending Fell 0.6% in December
Eli Lilly Reports Olumiant Setbacks in Lupus, Atopic Dermatitis
FTSE Down, Long Gilts Could Remain in Sweet Spot
Colgate-Palmolive Expects Earnings Growth This Year
Chevron Hits Production High in 2021, Net Output Down 5% in 4Q -- Energy Comment
Regeneron, Sanofi Pull FDA Application for Libtayo in Advanced Cervical Cancer
Bristol Myers Gets Positive CHMP Opinion For Breyanzi in Lymphoma
Colgate-Palmolive 4Q Profit Falls, Hit by Higher Costs
Merck: Molnupiravir Covid-19 Pill Effective Against Omicron in Lab Tests
EUROPEAN MIDDAY BRIEFING - Stocks Fall Ahead of Expected Mixed US Open
Insulet Gets FDA OK for Omnipod 5 Automated Insulin-Delivery System
North American Morning Briefing: S&P 500, Dow on Track for Fourth Weekly Loss
BOE Seen Trying to Encourage Stronger Pound, Says ING
Givaudan Shares Slide on Weak Profitability, Costs Impact
Belgian Economy Grew in 4Q at a Slower Pace
FTSE 100 Drops as Oil, Mining, Financial Stocks Fall
Henkel Shares Slide as 2022 Targets Fall Short of Consensus
jaybird249   Wednesday, 12/21/11 10:47:51 PM
Re: None
Post # of 241360 
BPAX is trading for less than cash (cash less long-term liabilities) plus residual pipeline value (even after the libigel disappointments)

Historically, stocks that have seen large drops in share price also can spike further in early January known as "January Poppers" effect.

BPAX has a PDUFA forward looking near term catalyst date on February 14 2011.

I have played many biotech 'failure' stocks for a hefty rebound successfully. Sometimes they bounce immediately, like OREX, last year when contrave was rejected by the FDA.

OREX went from about $2.40 to $4.10 in a few days.

Losing institutions have had to sell in order to push through and claim tax losses before end of year.

Similarly, institutions and big money who have won massively from being short - and their are 21 million of them! will want to push through their tax gains before end of year.

But To recognize their huge gains from BPAX shorts, they must COVER which will add upward pressure to the stock.

When a stock cliffdives such as BPAX, margin selling normally occurs for the first three days. This adds down pressure to the stock, of course.

http://finance.yahoo.com/q/hp?s=BPAX+His...

Expect volume to drop dramatically over the next couple of days as most of the big exits have already taken place.

How will the remaining millions of shorts (some covering has occurred) be able to cover without the needed volume without bidding up the share price?

Friday's drop was a last ditch attempt by shorts that are desparate to cover, to take out stop losses (yes, they know where stops are placed) and induce FUD (fear, uncertainty, doubt) in order to cover as profitably as possible.


Other times, these biotechs that have bombed, rebound a few days to a week or so later.

Unfortunately, only market makers know when that period will likely occur from their institutional order flows that are placed with them on the buy and sell sides.

These are just some of my humble opinions. Please do your own research.

Feel free to agree or disagree with the above, if you have reasons why you think buying in BPAX between .45 - .50 is or isn't a good trading opportunity for a bounce play.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences